Pliant Therapeutics Inc (NASDAQ:PLRX) price on Friday, June 13, fall -6.12% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.38.
A look at the stock’s price movement, the close in the last trading session was $1.47. Turning to its 52-week performance, $16.10 and $1.10 were the 52-week high and 52-week low respectively. Overall, PLRX moved 1.47% over the past month.
Pliant Therapeutics Inc’s market cap currently stands at around $84.72 million, with investors looking forward to this quarter’s earnings report slated for in July.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend PLRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PLRX’s current price about -4.17% and -4.05% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.48, while 7-day volatility ratio is 3.10% and 4.16% in the 30-day chart. Further, Pliant Therapeutics Inc (PLRX) has a beta value of 1.36, and an average true range (ATR) of 0.12. Analysts have given the company’s stock an average 52-week price target of $2.5, forecast between a low of $2 and high of $3. Looking at the price targets, the low is -44.93% off current price level while to achieve the yearly target high, price needs to move -117.39%. Nonetheless, investors will most likely welcome a -81.16% jump to $2.5 which is the analysts’ median price.
If we refocus on Pliant Therapeutics Inc (NASDAQ:PLRX), historical trading data shows that trading volumes averaged 1.19 million over the past 3 months. The company’s latest data on shares outstanding shows there are 61.39 million shares.
The 11.97% of Pliant Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 86.96% of the company’s shares. Current price change has pushed the stock -89.52% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PLRX stock continues to rise going into the next quarter.
